Cochrane · systematic review · CD011806
Vitamin D for the treatment of inflammatory bowel disease
Wallace, C, Gordon, M, Sinopoulou, V, et al. · Cochrane Database of Systematic Reviews · 2023 · Cochrane Library
GutAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
12
current version
GRADE rated
8
No studies
4
Included studies
NR
No studies 4 · 33.3%Ungraded 0 · 0%Very low 6 · 50%Low 2 · 16.7%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Vitamin D (all doses) compared to placebo/no treatment for the treatment of inflammatory bowel disease
Population: people with active or inactive inflammatory bowel disease of any age
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Clinical response at end of study (4 weeks) Vitamin D (all doses) vs placebo/no treatment | RR 4 [1.51, 10.57] | 1 study · 60 participants | Very low Downgraded: risk of bias, imprecision |
Clinical relapse at end of study (26–52) weeks Vitamin D (all doses) vs placebo/no treatment | RR 0.57 [0.34, 0.96] | 3 studies · 310 participants | Low Downgraded: risk of bias, imprecision |
Quality of life at end of study (26 weeks) Vitamin D (all doses) vs placebo/no treatment | no estimate extracted | 2 studies · 243 participants | Very low Downgraded: imprecision, inconsistency |
Withdrawals due to adverse events Vitamin D (all doses) vs placebo/no treatment | RR 1.97 [0.18, 21.27] | 12 studies · 1251 participants | Very low Downgraded: risk of bias, imprecision |
High‐treatment‐dose vitamin D (greater than 1000 IU/day) compared to low‐treatment‐dose vitamin D (400 IU/day to 1000 IU/day) for the treatment of inflammatory bowel disease
Population: people with active or inactive inflammatory bowel disease of any age
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Clinical response High‐treatment‐dose vitamin D (greater than 1000 IU/day) vs low‐treatment‐dose vitamin D (400 IU/day to 1000 IU/day) | no estimate extracted | NR | No studies |
Clinical relapse at end of study (52 weeks) High‐treatment‐dose vitamin D (greater than 1000 IU/day) vs low‐treatment‐dose vitamin D (400 IU/day to 1000 IU/day) | RR 0.48 [0.23, 1.01] | 1 study · 34 participants | Low Downgraded: imprecision |
Quality of life High‐treatment‐dose vitamin D (greater than 1000 IU/day) vs low‐treatment‐dose vitamin D (400 IU/day to 1000 IU/day) | no estimate extracted | 1 study · 46 participants | Very low Downgraded: risk of bias, imprecision |
Withdrawals due to adverse events High‐treatment‐dose vitamin D (greater than 1000 IU/day) vs low‐treatment‐dose vitamin D (400 IU/day to 1000 IU/day) | RR 0.89 [0.06, 13.08] | 3 studies · 104 participants | Very low Downgraded: risk of bias, imprecision |
Any‐treatment‐dose vitamin D (greater than 400 IU/day) compared to supplemental‐dose vitamin D (less than 400 IU/day) for the treatment of inflammatory bowel disease
Population: people with active or inactive inflammatory bowel disease of any age
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Clinical response Any‐treatment‐dose vitamin D (greater than 400 IU/day) vs supplemental‐dose vitamin D (less than 400 IU/day) | no estimate extracted | NR | No studies |
Clinical relapse Any‐treatment‐dose vitamin D (greater than 400 IU/day) vs supplemental‐dose vitamin D (less than 400 IU/day) | no estimate extracted | NR | No studies |
Quality of life Any‐treatment‐dose vitamin D (greater than 400 IU/day) vs supplemental‐dose vitamin D (less than 400 IU/day) | no estimate extracted | NR | No studies |
Withdrawals due to adverse events Any‐treatment‐dose vitamin D (greater than 400 IU/day) vs supplemental‐dose vitamin D (less than 400 IU/day) | RR 3.09 [0.13, 73.17] | 4 studies · 233 participants | Very low Downgraded: risk of bias, imprecision |